000 04036naa a22005177i 4500
001 UMUN-OA-20261005-MLS-027
003 local
005 20261005174903.0
006 m o d
007 cr||||||||||||
008 261005s2023 xx o u000 0 eng d
024 7 _a10.3390/genes14071314
_2doi
035 _a(local)EuropePMC:PMC10379610
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aBayan Alzumaili
_eauthor.
245 1 0 _aUpdate on Molecular Diagnostics in Thyroid Pathology: A Review. /
_cBayan Alzumaili; Peter M Sadow.
264 1 _a[Place of publication not identified] :
_bMultidisciplinary Digital Publishing Institute (MDPI),
_c2023.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aThyroid nodules are quite common, and the determination of a nodule of concern is complex, involving serum testing, radiology and, in some cases, pathological evaluation. For those nodules that raise clinical concern of neoplasia, fine needle aspiration biopsy is the gold standard for evaluation; however, in up to 30% of cases, results are indeterminate for malignancy, and further testing is needed. Advances in molecular testing have shown it to be of benefit for both diagnostic and prognostic purposes, and its use has become an integral part of thyroid cancer management in the United States and in several global nations. After The Cancer Genome Atlas (TCGA) consortium published its molecular landscape of papillary thyroid carcinoma (PTC) and reduced the "black matter" in PTC from 25% to 3.5%, further work ensued to clarify the remaining fraction not neatly attributed to the BRAF V600E -like or RAS -like phenotypes of the TCGA. Over the past decade, commercial molecular platforms have been refined as data accrues, and they increasingly cover most genetic variants of thyroid carcinomas. Molecular reporting focuses on the nodule tested, including related clinical information for that nodule (size of nodule, Bethesda category, etc.). This results in a comprehensive report to physicians that may also include patient-directed, clear language that facilitates conversations about nodule management. In cases of advanced or recurrent disease, molecular testing may become essential for devising an individual therapeutic plan. In this review, we focus on the evolution of integrated molecular testing in thyroid nodules, and how our understanding of tumor genetics, combined with histopathology, is driving the next generation of rational patient management, particularly in the context of emerging small, targetable therapeutics.
540 _aCreative Commons Attribution. See the linked licence for the applicable terms.
_uhttps://creativecommons.org/licenses/by/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
650 4 _aThyroid carcinoma
650 4 _aRas
650 4 _athyroid
650 4 _aThyroid cancer
650 4 _aMolecular Diagnostics
650 4 _aBraf
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _amolecular diagnostics
655 4 _aReview articles.
700 0 _aPeter M Sadow
_eauthor.
773 0 _tGenes
_gVol. 14, no. 7, (2023), pages/article 1314
_x2073-4425
856 4 0 _uhttps://europepmc.org/articles/PMC10379610
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC10379610
_qlocal
942 _n0
999 _c1169
_d1169